Information updates

Anapen® is TGA approved and recommended by PBAC for PBS Listing

Anapen 300®, Anapen 500® and Anapen 150 Junior® (Anapen Junior) adrenaline (epinephrine) autoinjectors have been approved by the Therapeutic Goods Administration (TGA) for the treatment of anaphylaxis (severe allergic reactions). 

The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the General Schedule Authority Required Pharmaceutical Benefits Scheme (PBS) listing of Anapen 300®, Anapen 500® and Anapen 150 Junior®. The Public Summary Documents from the November 2020 PBAC meeting are now available.

It is expected that Anapen 300®, Anapen 500® and Anapen 150 Junior® will be available in Australia on the PBS in September 2021. 

In preparation for the updating of ASCIA resources and e-training courses by July 2021, ASCIA has developed:

Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia